Key Takeaway: How Many Americans Use GLP-1
About 4 to 5 percent of U.S. adults report using a GLP-1 receptor agonist, based on the most recent nationally representative survey data available through early 2024. Among adults with obesity, usage is higher, with roughly 1 in 10 to 1 in 8 reporting use. Younger adults, women, and people with private insurance or lower out-of-pocket costs are more likely to report use. These estimates reflect a fast-moving landscape; coverage and prescribing patterns can shift quickly as guidelines, formularies, and patient access evolve.
What Are GLP-1 Medications
GLP-1 receptor agonists are a class of medicines that mimic the action of glucagon-like peptide-1, a hormone released after eating. They slow gastric emptying, promote satiety, and affect appetite regulation in the brain. Originally developed for type 2 diabetes, specific GLP-1 drugs at higher doses are now widely prescribed for chronic weight management in adults with obesity or overweight with weight-related conditions. Common examples include semaglutide and tirzepatide. While highly effective for many people, these medications require ongoing medical supervision and are associated with side effects, contraindications, and variable access and affordability.
Recent Estimates of Use in the U.S.
Nationwide surveys and claims data suggest that GLP-1 use among U.S. adults has risen noticeably in the past few years but remains concentrated among certain groups. The estimates below synthesize findings from large household surveys and pharmacy claims, with the most reliable data generally coming from sources that use representative sampling and verified prescription records. Because measurement approaches differ, estimates vary; the range below captures best available evidence through early 2024.
| Metric | Estimate or Range | Primary Source Type |
|---|---|---|
| Percent of U.S. adults using a GLP-1 | About 4–5% | National health interview surveys and prescription claims (early 2024) |
| Percent among adults with obesity | Approximately 10–15% | Claims and survey data stratified by weight status |
| Common medications reported | Semaglutide, tirzepatide | Prescription monitoring and survey open-text responses |
| Most common age band among users | Adults 35–64 | Prescription fills and patient surveys |
How Usage Varies Across Groups
GLP-1 use is not evenly distributed across the population. Understanding these patterns helps contextualize the overall percentage and highlights disparities in access and treatment intensity.
- Age: Usage rises through middle age, peaking among adults aged 35–64, and is lower among younger adults and seniors, partly due to differences in obesity prevalence and access dynamics.
- Sex: Women are more likely than men to report use, often reflecting higher rates of engagement with weight management care and, in some settings, differences in cost-sharing or formulary positioning.
- Insurance and cost: People with private insurance and lower out-of-pocket requirements report higher use, while those on public plans or with high cost-sharing are less likely to fill prescriptions, even when medically eligible.
- Geography and practice: Use is higher in regions and health systems with more intensive prescribing practices and better integration of pharmacist-led support for initiation and follow-up.
Clinical, Coverage, and Access Considerations
GLP-1 medications require medical evaluation, ongoing monitoring, and often dose adjustments. Access can be affected by prior authorization, quantity limits, and formularies. In some health systems, patients face wait times or stepped-care requirements before they can receive higher-dose formulations for weight management. Out-of-pocket costs, even with insurance, can be significant, influencing persistence and adherence. Conversely, robust support programs, including telehealth follow-up and pharmacist coordination, have been associated with higher persistence and better outcomes.
What This Means at the Population Level
At a population level, a 4 to 5 percent usage rate among U.S. adults means that millions of people are using GLP-1 medications, with numbers rising as prescribing expands and as payers adjust coverage policies. Yet substantial unmet need remains, shaped by cost, access, clinical eligibility, and awareness. For health systems and policymakers, understanding who is and is not using these medications can guide benefit design, patient education, and outreach to reduce inequities and improve appropriate use over time.